When the FDA approved Casgevy as the first therapy using CRISPR gene-editing technology in 2023, sickle cell anemia patients and their caregivers were astonished, hopeful, and concerned. It had been ...
In today’s fast-paced, resource-constrained environment, businesses are constantly seeking new ways to optimize employee performance, improve training outcomes, and ensure the readiness of their teams ...